1.Cost analysis of a Patient-Centred Medical Home for community-dwelling older adults with complex needs in Singapore.
Grace SUM ; Mumtaz Mohamed KADIR ; Soon Hoe HO ; Joanne YOONG ; Junxing CHAY ; Chek Hooi WONG
Annals of the Academy of Medicine, Singapore 2022;51(9):553-566
INTRODUCTION:
The Patient-Centred Medical Home (PCMH) demonstration in Singapore, launched in November 2016, aimed to deliver integrated and patient-centred care for patients with biopsychosocial needs. Implementation was based on principles of comprehensiveness, coordinated care and shared decision-making.
METHOD:
We conducted a prospective single-arm pre-post study design, which aimed to perform cost analysis of PCMH from the perspectives of patients, healthcare providers and society. We assessed short-to-intermediate-term health-related costs by analysing data on resource use and unit costs of resources.
RESULTS:
We analysed 165 participants enrolled in PCMH from November 2017 to April 2020, with mean age of 77 years. Compared to the 3-month period before enrolment, mean total direct and indirect participant costs and total health system costs increased, but these were not statistically significant. There was a significant decrease in mean cost for primary care (government primary care and private general practice) in the first 3-month and second 3-month periods after enrolment, accompanied by a significant decrease in service utilisation and mean costs for PCMH services in the second 3-month period post-enrolment. This suggested a shift in resource costs from primary care to community-based care provided by PCMH, which had added benefits of both clinic-based primary care and home-based care management. Findings were consistent with a lower longer-term cost trajectory for PCMH after the initial onboarding period. Indirect caregiving costs remained stable.
CONCLUSION
The PCMH care model was associated with reduced costs to the health system and patients for usual primary care, and did not significantly change societal costs.
Aged
;
Health Care Costs
;
Humans
;
Independent Living
;
Patient-Centered Care
;
Prospective Studies
;
Singapore
2.Initiating or switching to insulin degludec/insulin aspart in adults with type 2 diabetes in Malaysia
Mafauzy Mohamed ; Siang Chin Lim ; Malik Mumtaz ; Shweta Uppal ; Deepak Mukherjee ; Mohamed Saiful Mohd Kassim ; Shalini Sreedharan ; Amudha Murugan Doraiswamy ; Kuck Meng Chong ; Lu Yu Tat ; Sudzilla Binti Nordin ; Jeshen Lau Hui Giek ; Zanariah Hussein ; Khalid Abdul Kadir ; Bik Kui Lau ; Siew Pheng Chan
Journal of the ASEAN Federation of Endocrine Societies 2023;38(1):37-44
Objectives:
Insulin degludec (IDeg)/insulin aspart (IAsp; IDegAsp) is a co-formulation of 70% IDeg and 30% IAsp. According to several randomized controlled trials, IDegAsp is effective and safe for patients with type 2 diabetes mellitus (T2DM). A subgroup analysis of the ARISE study was conducted to explore the safety and efficacy of IDegAsp among Malaysian patients with T2DM in real-world settings.
Methodology:
ARISE, an open-label, multicenter, non-interventional, prospective study was conducted between August 2019 and December 2020. Adult Malaysian patients with T2DM who were enrolled from 14 sites received IDegAsp as per the local label for 26 weeks. The primary endpoint was change in glycated hemoglobin (HbA1c) levels from baseline
to end of study (EOS).
Results:
Of the 182 patients included in the full analysis set, 159 (87.4%) completed the study. From baseline to EOS, HbA1c (estimated difference [ED]: –1.3% [95% CI: –1.61 to –0.90]) and fasting plasma glucose levels (ED: –1.8 mmol/L [95% CI: –2.49 to –1.13]) were significantly reduced (p<0.0001). The patient-reported reduced hypoglycemic episodes (overall and nocturnal) during treatment. Overall, 37 adverse events were observed in 23 (12.6%) patients.
Conclusion
Switching or initiating IDegAsp treatment resulted in significant improvements in glycemic control and a reduction in hypoglycemic episodes.